Skip to main content
. 2012 Aug 13;22(3):483–491. doi: 10.1089/scd.2012.0201

FIG. 4.

FIG. 4.

Effects of hypoxia on VEGF production and cell viability of nonviral engineered ADSCs. (a) Hypoxia (1% O2 for 48 h) enhanced VEGF release from nonviral engineered ADSCs in a dose-dependent manner. (b) Hypoxia treatment led to an increase in ADSC viability in most PBAE-transfected groups, except in the groups transfected with 6 μg PBAE/DNA or Lipo.